KIT and renal fibrosis: Treatment with KIT-bFGF (21.80 ± 2.47%, 16.36 ± 7.72%) significantly attenuated renal fibrosis (blue staining), and the fibrotic area was significantly smaller than that in the bFGF-treated (30.62 ± 4.03%, 36.59 ± 5.20%) and PBS-treated (50.76 ± 5.77%, 44.51 ± 8.11%) groups.